The pharmaceutical industry has always been a relatively closed industry.The pharmaceutical industry is always separated from the outside world by a complex and unshared knowledge of pharmacy.Now that wall is breaking down because of digital technology.More and more artificial intelligence enterprises begin to cooperate with drug developers to apply artificial intelligence technology to each link of new drug research and development and accelerate the new drug research and development process.
Recently, AI+ new drug market has frequently received good news, and many enterprises have completed high financing in 2020.
In June 2010, The Drug Discovery Today published a short review, “The Upside of Being a Digital Pharma Player”, which analyzed The current status of AI applications in The R&D departments of 21 pharmaceutical giants worldwide from 2014 to 2018.The results show that the FIELD of AI+ new drugs, though still in its early stages, is maturing.
According to statistics, as of October 16, 2020, a total of 56 AI+ new drug companies at home and abroad have obtained financing, with a total accumulated financing amount of $4.581 billion.Among them, 37 foreign companies have obtained financing with a total cumulative total of 31.65 US dollars, and 19 domestic companies have obtained financing with a total cumulative total of 1.416 billion US dollars.
Post time: Nov-03-2020